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INTRODUCTION 
Inflammation is the body’s protective reaction to harmful 
stimuli such as mechanical injury, chemical toxins, 
invasion by microorganisms, and hypersensitivity 
reactions. Inflammatory process involves host defense 
cells (platelets, granulocytes (PMNs, mast cells etc.), 
monocytes/macrophages, lymphocytes, and fibroblasts), 
blood vessels and protein. The main goal of 
inflammation is to bring the defense cells (immune cells) 
to the area of concern which is commonly mediated by 
chemicals like cytokines produced by damaged host 
cells, eliminate the initial cause of injury, remove 
necrotic cells and tissue as well as to initiate the process 
of healing (Kumar et.al. 2012). 
 
Inflammation may be acute or chronic. Acute 
inflammation has an immediate reaction that lasts for a 
short duration (8-10 days) and the cellular infiltrate 
mainly contains neutrophils. It is characterized by 
vasodilation, vascular leakage and edema, as well as 
leukocyte emigration to extravascular tissue. The 
classical symptoms of acute inflammation include heat 
(calor), redness (rubor), swelling (tumor), pain (dolor) 
and loss of function (Rankin, 2004). 
 
On the other hand, chronic inflammation is a sequel of 
acute inflammation that lasts for several weeks to years 
and characterized by reduction on numbers of 
neutrophils and increased infiltration of macrophages, 
lymphocytes, plasma cells, and fibroblasts (Goldsmith 
and Vallabhajosula, 2009). 
 
Inflammation is normally controlled and self-limited. 
However, components of the inflammatory process may 
destroy normal tissue and inappropriate inflammatory 
processes (autoimmune reaction) may lead to disorder 
(Kumar et.al. 2012). 
 
Infection is the invasion of a host organism's bodily 
tissues by disease-causing organisms (virus, fungus or 
bacteria), their multiplication and the reaction of host 
tissues to these organisms and the toxins they produce 
(Stolberg, 1998). From the definition we understand that, 
infection is just one of the possible causes of 
inflammation. 
 
Infectious and inflammatory diseases are common causes 
of morbidity and mortality worldwide. Rational 
diagnosis of infection and inflammation is invaluable for 
better outcome and overall costs of the disease 
management in which radiopharmaceuticals play an 
important role. Several radiopharmaceuticals have been 
developed in the last decade for infection and 
inflammation imaging. Some of them have been used in 
clinical practice and many others are still in preclinical 
and clinical studies. 
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ABSTRACT 
The diagnosis of infectious and inflammatory disorders is still challenging. Molecular imaging using 
radiopharmaceuticals continues to play an important role in the diagnosis and monitoring of infectious and 
inflammatory disorders because it gives information about the site of the lesion and the molecular and functional 
patterns of the disorders. The aim of this review is to describe the strengths and limitations of these 
radiopharmaceuticals. Many radiopharmaceuticals have been developed. Even though none of them is ideal each 
one has its own strengths and weaknesses. Many radiopharmaceuticals have been studied but still only few of them 
are in clinical practice today. Therefore, it is important to accelerate the development of clinically viable 
radiopharmaceuticals for this area. 
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Fever of unknown origin (FUO) is a rise of body 
temperature above the normal (38.3°C or more) on and 
off for at least 3 weeks with no known cause. Studies 
show that it may be caused by infections, noninfectious 
inflammatory disorders, malignancies, collagen vascular 
disease, granulomatous diseases, pulmonary embolism, 
cerebrovascular accidents, drug induced fever, etc. (Roth 
and Basello, 2003). Radiopharmaceuticals have also 
played a huge role in differentiating the cause of FOU 
(Meller and Becker, 2001). 
 
Currently, the diagnosis of infections and inflammatory 
diseases depends on patient history taking, physical 
examination, in vitro tests, endoscopy and imaging 
techniques; such as molecular imaging. Molecular 
imaging is a technique in which the imaging is targeted 
to specific molecular or cellular features. It has important 
advantages over the other diagnostic methods in that 
apart from giving information about the location of the 
lesions, it also provides the much needed information 
about the molecular and functional aspects of the disease. 
This is particularly useful for not only differentiating 
between infection and sterile inflammation, but may also 
point out the specific infectious organisms involved and 
inform treatment decisions. 
 
Molecular imaging techniques include radionuclide 
imaging, optical imaging, X-Ray Computed Tomography 
(CT), ultrasound molecular imaging and magnetic 
resonance imaging (Chen, 2014). Radionuclide imaging 
and optical imaging are generally considered to be 
functional imaging techniques while magnetic resonance 
imaging, CT and Ultrasonography provide anatomical or 
structural data. Features of radionuclide imaging that 
give it a competitive edge above other imaging 
modalities are its high sensitivity, high specificity, it is 
also quantitative and it has a limitless tissue depth. The 
lack of anatomical data and poor resolution of this 
technique has been compensated for by using 
multimodality imaging in which radionuclide imaging is 
coupled with either magnetic resonance imaging or, 
more commonly, with CT. 
 
Common radionuclide imaging techniques for clinical 
usage are Single Photon Emission Computed 
Tomography (SPECT) and Positron Emission 
Tomography (PET). SPECT is more popularly used than 
PET, partly because it is cheaper (Chen, 2014). 
However, the clinical application of PET imaging is 
gaining ground owing to its better sensitivity and spatial 
resolution (Rahmim, 2008). To improve their clinical 
utility, these imaging modalities have been fused with 
other imaging modalities such as MRI and CT into 
hybrid imaging systems such as SPECT/CT, PET/CT, 
PET/MRI, etc. (Cherry, 2009). Globally, the clinical 
application of hybrid PET-based systems is growing 
faster than single modality PET systems (Hricak, 2010). 
 
The ideal radiopharmaceuticals for the imaging of 
infection and inflammation foci should have high 
sensitivity for infection/inflammation, differentiate 
between infection and inflammation, differentiate 
between acute and chronic infection, no toxicity and/or 
immunogenic response, minimum radiation burden to the 
patient and worker, high specificity, rapid clearance from 
circulation, no uptake in gastrointestinal tract, as well as 
they should be easy to prepare, have low cost and wide 
availability (Goldsmith and Vallabhajosula, 2009). 
 
Unfortunately, no radiopharmaceutical used to image 
infection and inflammation foci has ever achieved all the 
ideal characteristics. The aim of this review is to describe 
the strengths and limitations of the currently available 
radiopharmaceuticals for application in this area. 
 
SPECT Radiopharmaceuticals 
SPECT radiopharmaceuticals remain the prime choice 
for the nuclear imaging of infections and inflammatory 
disorders in most clinical practice because of availability, 
low cost, and longer half-life of the radionuclides as well 
as relatively lower radiation dose to the patients 
compared to most PET radiopharmaceuticals. 
 
Gallium-67 based radiopharmaceuticals for infection 
and inflammation imaging 
Gallium is a group three element in the periodic table. It 
has an electronic configuration of Ar[3d104s24p1], hence, 
it mainly adopts a +3 charge in its compounds. It readily 
forms complexes with compounds that have nitrogen and 
oxygen as the donor ligands (Engesser, 2016). The three 
radioisotopes of gallium that have potential clinical 
applicability are gallium-67, gallium-68 and Gallium-66. 
However, the commonest are gallium-67 and gallium-68 
due to their more favorable decay properties. 
 
Radioisotopes of Gallium have important strengths in 
inflammation and infection imaging. As Iron (III), free 
gallium readily chelates with transferrin and lactoferrin 
which are abundant in inflammation loci. Also, it readily 
chelates with siderophores that are produced by bacteria 
in areas of bacterial infection (Tsan, 1985). 
 
Gallium -67 
Gallium-67 decays 100% through electron capture, with 
a half-life of 3.26 days. In the process, it emits gamma 
rays of various energies. The gamma rays of the energies 
93 keV, 185 keV and 300 keV are clinically useful. The 
abundances of these rays are 39%, 21% and 17% 
respectively (Delacroix et al, 2002). Gallium-67 is 
obtained for radiopharmaceutical application, commonly 
through cyclotron irradiation of Zinc-68 targets with 
proton beams (Arzumanov, 2000). 
 
Gallium-67 has a long enough half-life, allowing for 
longitudinal imaging of the infection or inflammation 
locus for up to one week. The long half-life is also useful 
for delayed imaging if it’s part of slow-clearing 
radiopharmaceuticals. Despite that, its cyclotron 
production makes the radioisotope more costly than 
generator produced radioisotopes. Another limitation is 
Janevik et al.                                                                   European Journal of Pharmaceutical and Medical Research 
 
www.ejpmr.com 
 
 
 
172 
that its clinically useful gamma radiations are of low 
abundance. 
 
Gallium citrate is the oldest radiopharmaceutical to be 
used in infection and inflammation imaging. Previously 
it had been used for the diagnosis of cancer (Lavender et 
al 1971). Its localization at the site of infection and 
inflammation is assumed to be due to Ga3+ dissociating 
from citrate and chelating to blood transferrin 
(Vallabhajosula et al, 1980). Then this complex 
extravasates to the site of inflammation due to increased 
capillary permeability. It also binds to lactoferrin and 
bacterial siderophores (Tsan, 1985) that are abundant at 
the sites of inflammation and infection respectively. 
 
It has been used for the detection of vertebral 
osteomyelitis, chronic osteomyelitis, septic arthritis, 
cellulitis, and opportunistic infections in 
immunocompromised patients such as pulmonary 
infections as well as for the detection of FUO (Kalabat 
and Powsner, 2004). 
 
Despite its usage, gallium citrate has its own limitations 
including low specificity due to its excretion through 
bowel, accumulation in malignant and bone remodeling 
areas. The high energy gamma rays lead to poor quality 
image and high radiation absorbed dose. Also, delayed 
imaging is required for optimal images to be achieved. 
 
Because of the challenges associated with the 
radionuclide’s nuclear characteristics there was need to 
explore other radionuclides with better radiation 
characteristics than gallium -67. 
 
Indium-111 based radiopharmaceuticals for infection 
and inflammation imaging 
Indium is a group thirteen element in the periodic table 
of elements. It has an electronic configuration of 
[Kr]4d105s25p1. Its chemistry is intermediate between 
that of its congeners gallium and that of thallium in that 
apart from its usual +3 oxidation state (Wadas, 2010), 
some compounds in which it exists as +1 oxidation state 
have also been reported (Engesser, 2016). 
 
Indium-111 decays to cadmium-111 100% through 
electron capture with half-life of 2.80 days. It also emits 
clinically useful gamma rays of energies 171 keV and 
245 keV, each with an abundance that is greater than 
90% (Be, 2006). Due to its chemistry, its long half-life 
and its high abundance of gamma rays with suitable 
energies, In-111 is one of the important radioisotopes for 
infection and inflammation imaging. One the other hand, 
the high abundance of both gamma rays can lower the 
image quality. 
 
Several ligands can be labelled with indium-111 and 
used for imaging infection and inflammation foci. 
Ligands such as human immunoglobulins G polyclonal 
antibody, monoclonal antibodies, white blood cells, 
streptavidin-biotin, bacterial chemotactic peptides and 
liposomes are among the examples. The main advantage 
of using indium to label with ligands for clinical 
application is its long half-life (67 hours) allow imaging 
beyond 24 hr. post injection. 
 
However, suboptimal photon energies, low resolution 
images, long time from injection to imaging acquisition 
in the case of white blood cells (Palestro et.al 2009) and 
the better imaging characteristics of technetium-99m for 
gamma camera (physical characteristics, availability, 
cost and lower radiation burden) challenges indium-
111’s application in the detection of infection and 
inflammation foci (de Vries et.al. 2010). 
 
Technetium-99m based radiopharmaceuticals for 
infection and inflammation imaging 
Technetium is an atomic number 43 transition metal with 
an electronic configuration of [Kr]5s24d5, found in the 
group seven of the periodic table of elements. It can exist 
in as many as nine oxidation states; -1 to +7. Its 
chemistry is versatile in that it forms stable complexes 
with a large variety of donor and acceptor ligands, 
producing a wide range of inorganic functional groups 
(Duatti, 2011). Thus, the chemistry of technetium offers 
itself as an important asset for extensive 
radiopharmaceutical application. 
 
Technetium-99m is still the most predominant 
radioisotope in radiopharmaceuticals, accounting for 
over 80% of all radiopharmaceuticals used worldwide 
(Neilly, 2015). It decays over 99.99% by isomeric 
transition to technetium-99. Its decay half-life is 6.0 
hours and it emits gamma rays of 141 keV, with 89% 
abundance (Delacroix, 2002), which are highly suitable 
for nuclear imaging. Technetium-99m is a hugely 
advantageous radioisotope in infection and inflammation 
imaging because of the versatile technetium chemistry 
and its equally important nuclear properties. Since it is 
primarily available through a commercial GMP 
compliant generator, it is cheaper than many other 
radioisotopes used in radiopharmaceuticals such as the 
cyclotron produced radioisotopes. The 66-hour half-life 
of the parent molybdenum-99 radionuclide allows for a 
two week working life of the generator, thereby allowing 
for efficient supply logistics. 
 
However, technetium-99m does not decay to a stable 
isotope. Instead, it decays to technetium-99 which is a 
long lived beta emitter. Technetium-99 has the same 
chemistry as technetium-99m, allowing it to compete 
with technetium-99m and reduce radiolabeling yield. 
Another limitation of Moly generator produced 
technetium-99m is its unavoidable presence of 
technetium-99 impurity because 12.4 % of Molybdenum-
99 decays directly to tecnetium-99 (Be, 2004). 
 
Ligands to be labeled with technetium include a wide 
variety of molecules such as blood cells, antibodies, 
peptides, antimicrobial agents, cytokines, liposomes, etc. 
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White blood cells (WBCs) 
Chemotactic migration of WBCs to the sites of infection 
and inflammation is a natural immune defense 
mechanism. Radiolabeled WBCs have shown significant 
accumulation at the site of infection and inflammation 
foci. WBCs have been effectively labelled with Tc-hexa-
methyl propylene amino oxime (HMPAO) (Peters et.al 
1986). 
 
99mTc-HMPAO-labelled WBCs have been used for 
diagnosis of various infection and inflammation 
disorders including occult infection, inflammatory bowel 
disease, osteomyelitis, follow-up of patients with 
infections of vascular or orthopedic prosthesis, FOU, 
postoperative abscesses, lung infections, endocarditis, 
neurological infections and infected central venous 
catheters or other devices (de Vries et. al 2010). 99mTc-
HMPAO-WBCs scintigraphy is considered as a gold 
standard method for detection of acute infections. Some 
advantages of this method are that it may selectively 
differentiate infection from inflammation, it is devoid of 
allergy reactions since patients own blood is reinjected 
and it achieves better anatomical localization of infection 
sites (Love and Palestro, 2004). Despite a wide usage of 
99mTc-HMPAO-WBC, it has important drawbacks. For 
example, it is mainly effective in immunocompetent 
patient. For immunocompromised patients such as 
infected with HIV, patients receiving immune 
modulating agents and for infections that do not elicit 
strong immune responses such as Mycobacterium 
tuberculosis or Pneumocystis carinii, white blood cell 
labelling is not a choice to image infection and 
inflammation foci (Palestron and Torres, 1999). In 
addition, it is contraindicated in patients suffering from 
neutropenia because there is difficulty in obtaining 
sufficient amounts of WBCs to label. Sometimes, it is 
nonspecific. Also, false negative results in chronic 
infection may occur due to low granulocyte involvement 
in chronic infectious diseases. Preparation is time 
consuming, laborious, needs special facilities and carries 
a high risk of contamination (Petruzzi et.al.2009 & de 
Vries et. al 2010). 
 
In addition, the 99mTc-HMPAO labelled WBCs have less 
in vivo stability than the indium-111 labeled WBCs. One 
example is the in vivo release of 99mTc-HMPAO from 
the labeled WBCs after reinjection into the patients. The 
free 99mTc-HMPAO is excreted via the hepatobiliary 
systems and the kidneys, which may hamper image 
interpretation. This phenomenon is not observed with 
111In-oxine labelled WBCs (Signore et.al 2009) and the 
normal distribution of indium labelled WBCs is confined 
to liver, spleen and bone marrow. (Palestro et.al 2009). 
To avoid the above limitations, other ligands have been 
developed. Some of the important ligands include human 
immunoglobulins G antibody, Antigralocyte antibodies, 
small peptides etc. 
 
 
 
Antibodies 
One of the methods of avoiding the limitations of 
radiolabeling WBCs in vitro is to radiolabel them in vivo 
using radiolabeled antibodies. The radiolabeled 
antibodies may bind to antigens on the WBCs and move 
to the site of infection and inflammatory foci by 
chemotaxis. Examples of antibody-based ligands are 
human immunoglobulin G, antigranulocyte antibodies 
and their fragments. Unlike radiolabelled WBCs, they 
don’t require sophisticated methods of preparation. 
 
Human immunoglobulins G antibody 
It is a polyclonal antibody secreted in response to tissue 
damage. It can be isolated from human blood and used to 
enhance immunity in immunocompromised patients and 
other conditions which need immunity boost 
(Widjaksana et.al 2008). 
 
Technetium-99m labelling of human immunoglobulin G 
is achieved via direct labelling and indirect methods. The 
direct method is where immunoglobulin’s the disulfide 
bonds are reduced by reducing agents such as SnCl2 and 
then the resultant sulfhydryl groups serve as binding sites 
for reduced technetium-99m. The indirect method of 
labelling requires a bifunctional chelator that attaches to 
both the antibody and the technetium-99m (Hnatowich 
et.al, 1993). Technetium-99m labelled human 
immunoglobulin G has been used to detect and localize 
musculoskeletal infections, rheumatoid arthritis and 
pulmonary infections; particularly in 
immunocompromised patients (Goldsmith and 
Vallabhajosula, 2009). The advantages of technetium-
99m labeled human immunoglobulin G antibody include 
the minimized possibility of allergy reactions as human 
immunoglobulin G is naturally found in the human body. 
Other advantages are that human immunoglobulin G is 
already commercially available as clinically proven safe 
IgG formulations for intravenous injection, it is possible 
to formulate it as a lyophilized kit formulation for long 
term storage and it does not require the sophisticated 
preparation methods for radiolabeling WBCs (Wong et.al 
1995). 
 
However, it is nonspecific as it does not discriminate 
infection from sterile inflammation, it has slow clearance 
from the circulation and from non-target tissues and also 
shows slow accumulation in target lesions; to long time 
intervals between radiopharmaceutical administration 
and final diagnosis (24-48hr), (Rubin and Fischman, 
1994). In addition, its high uptake in the liver, the spleen, 
and the kidneys makes it difficult to detect infection foci 
near to these tissues. Initially it was thought that the 
labelled human immunoglobulin G interacts with Fc-Y 
receptor that is expressed on infiltrating leucocyte. 
Nowadays, its accumulation at the site of infection and 
inflammation foci has been shown to occur by 
nonspecific extravasation due to the locally enhanced 
vascular permeability (Fischman et.al. 1992). Based on 
the same idea, monoclonal antigranulocyte antibodies 
were also developed with the hope that they will be 
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transported to the target loci by specifically bind to 
granulocytes. 
 
Antigranulocyte antibodies 
Anti-granulocyte antibodies are monoclonal antibodies 
that recognize and bind to specific antigens on 
granulocytes. Several anti-granulocyte antibodies have 
been identified of which anti-NCA-95 IgG 
(BW250/183), anti-NCA-90 Fab’ (Immu-MN3, 
Sulesomab: anti-CD66), and anti-SSEA-1 IgM 
(LeuTech: anti-CD15) were radiolabeled with 
technetium-99m for detection of infection and 
inflammation foci and they showed significant 
accumulation in the target foci (Becker et. al. 1994). 
Their advantage over radiolabelled polyclonal 
immunoglobulins is that they have excellent target to 
background ratio. 
 
Initially, whole antigranulocyte antibodies were 
radiolabeled but their slow clearance from the circulation 
and non-target sites and their risk of causing allergic 
reactions necessitated the development of 
radiopharmaceuticals based on antibody fragments. 
Consequently, more antigranulocyte antibody fragments 
than whole antigranulocyte antibodies have been labelled 
with technetium-99m. Sulesomab is an example of the 
antigranulocyte antibody fragments. It is an anti-CD15 
antibody Fab’ antibody fragment that has been labelled 
with technetium-99m and used to determine location and 
extent of infection and inflammation in bones with 
suspected osteomyelitis (including diabetic foot ulcers) 
(Delcourt et.al 2005). Also, it has shown its effectiveness 
in the detection of several infection and inflammation 
disorders including malignant external otitis and 
inflammatory bowel disease (Quigley et al. 2008 & 
Galletti et.al. 2015). However, their mechanism of 
localization at infection and inflammation foci appears to 
be different from radiolabeled WBCs. They are 
nonspecific in differentiating infection and sterile 
inflammation. Their uptake is still due to enhanced 
vascular permeability at the target foci (Petruzzi, 2009). 
Other limitations are: HAMA to the non-humanized 
antibodies, slow diffusion into sites of inflammation due 
to high molecular weight, long plasma half-lifes and high 
liver uptake due to their clearance by the reticulo-
endothelial system (Wang et.al. 2008). 
 
Ligands that were thought to possess less of the above 
limitations have been explored too. Examples include 
cytokines, microbial chemotactic peptides, antimicrobial 
peptides, etc. 
 
Low molecular weight peptides 
Cytokines 
Cytokines are a group of small proteins that are secreted 
by immune cells for cell signaling of inflammatory cells. 
Their receptors are found in leucocytes. Cytokines 
include chemokines, interferons, interleukins, 
lymphokines, and tumour necrosis factors (Luster, 1998). 
 
Interleukin 8 (IL-8) is a chemotactic cytokine that binds 
with a high affinity to its receptors expressed on 
activated neutrophils (Shahzad et.al. 2010). It is the most 
commonly radiolabeled interleukin for imaging infection 
and inflammation foci. It has been radiolabeled indirectly 
with 99mTc using HYNIC as a bifunctional complexing 
agent. 99mTc-labeled IL-8 has been studied in both 
humans and animals, showing promising results. It may 
be used for detection of pulmonary infections, 
osteomyelitis, and inflammatory bowel disease as well as 
other infectious and inflammatory disorders (Bleeker-
Rovers 2007). 
 
The advantage of technetium-99m labeled interleukin 
8(IL-8) radiopharmaceuticals is that they can be made 
available as lyophilized kits. They are also rapidly 
cleared from the circulation and non-targets tissues so 
that focal accumulation to sites of infection occurs as 
early as 4 hours after injection (Bleeker-Rovers 2007 & 
Gratz et.al 2001). 
 
Inability to discriminate infection and inflammation foci 
and lack of clinical trial studies are the major drawbacks 
of interleukin based radiopharmaceuticals. 
 
Microbial chemotactic peptides 
Microbial chemotactic peptides are small molecules 
released from bacteria that initiate migration of 
inflammatory cells (chemotaxis) by binding to high-
affinity receptors on the WBC’s cell membranes. They 
stimulate biological functions such as degranulation, 
release of oxygen radicals, phagocytosis, and eicosanoid 
production. They are usually formed via the cleavage of 
bacterial mitochondrial proteins (Nast and LeDuc, 1988). 
The tripeptide, formyl-methionyl-leucyl phenylalanine 
(f-MLF), has been labelled with technetium-99m via its 
HYNIC conjugate (99mTc-fMLFK-HYNIC) and showed 
preferential accumulation in both infection foci and foci 
of sterile inflammation in rabbits within 2 hour post-
injection (Edwards et.al 1999). 
 
Chemotactic peptides can be synthesized chemically, 
withstand harsh condition during preparation and 
labelling, and they are less likely to induce immunogenic 
reactions. In addition, they have rapid clearance from 
circulation hence earlier imaging is possible (Okarvi, 
2001). 
 
The main limitation with microbial chemotactic peptides 
is that they cause leucopenia at low dose (Das et.al. 
2002). In addition, they cannot differentiate between 
infection and sterile inflammation. Some peptides that 
were intended to localize specifically to infectious foci 
have been investigated. 
 
Antimicrobial peptides 
Antimicrobial peptides are biomolecules that exist in 
eukaryotes as a (innate immunity) defense mechanism 
against pathogenic microorganisms. Around 1500 
antimicrobial peptides have been discovered or 
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synthesized up to date. They are classified based on their 
amino acid composition and secondary structures. They 
show broad spectrum of activity against bacteria, viruses 
and fungi (Izadpanah and Gallo, 2005). 
 
Antimicrobial peptides selectively bind to pathogenic 
microorganisms due to differences in the physiological 
membranes of the host and the microorganisms such as 
membrane composition, charge, hydrophobicity, 
asymmetry, transmembrane potential and the existence 
of receptors in the pathogenic microorganism’s 
membrane for the antimicrobial peptides (Bahar and 
Ren, 2013). 
 
Antimicrobial peptides have attracted interest for specific 
imaging of infection foci because of their selective 
cytotoxicity to pathogenic microbes and their ability to 
selectively accumulate at the infection sites. In addition, 
they are cleared rapidly from the circulatory system and 
they rapidly accumulate at the infection foci. (Ebenhan 
et.al. 2014). 
 
Among the antimicrobial peptides, ubiquicidin and its 
fragments are the most studied. Ubiquicidin (UBI) 29–
41, is a fragment having amino acid sequence of 
TGRAKRRMQYNRR and a weight of 1,693 Da. It has 
been labelled with technetium-99m and shown promising 
results in clinical trials (Akhtar et.al 2005). 
 
Techntium-99m- ubiquicidin (UBI) 29-41 may be used 
for detection of infections in diabetic foot, hip 
prostheses, or other implant related infections. Moreover, 
it may also detect osteomyelitis and infective 
endocarditis (Akhtar et.al 2012). 
 
The drawback of this radiopharmaceutical is that 
antimicrobial efficacy and mechanisms are extremely 
sensitive to conditions such as pH, osmotic strength, 
solution viscosity, and temperature. Some bacteria 
produce proteases and degrade these peptides and lead to 
false negative results (enzymatic degradation). 
Furthermore, it does not detect infections caused by 
intracellular pathogens (Akhtar et.al 2012). Therefore, 
antimicrobial agents have been researched. 
 
Antimicrobials agents 
There has been a belief that radiolabeled broad spectrum 
antimicrobials that act by binding to specific 
microorganism’s components may possess an ability to 
differentiate infection foci from sterile inflammation 
foci. Consequently, fluoroquinolones, cephalosporins, 
penicillins and some other antimicrobial agents were 
radiolabeled with technetium-99m and used for detection 
of infection foci. (Shahzadi et.al 2015 & Lambrecht, 
2011). 
 
Radiopharmaceuticals that have been prepared using 
antimicrobial agents have ease and low cost of 
preparation, can be availed in kit forms and they are a 
better choice for immunocompromised patients since 
they do not interact with cells involved in the 
inflammatory and immune processes (signh. et.al 2012). 
 
However, in some studies it was observed that 
ciprofloxacin, the most commonly studied radiolabeled 
antibacterial, also localizes in sterile inflammation sites. 
Radiolabeled ciprofloxacin accumulates at the sites of 
infection and Inflammation foci because of increased 
vascular permeability (Sarda et.al. 2003). Furthermore, 
antimicrobial resistance may prevent the binding of the 
radiopharmaceutical to the bacteria, leading to false 
negative results. Problems relating to low radiochemical 
purity and poor stability have questioned its future 
application (Welling et. al 2001). Other nonspecific 
radiopharmaceuticals that base on technetium-99m 
include liposomes, nanocolloids, and MDP. 
 
Liposomes 
Liposomes are spherical vesicles made out of one or 
more lipid bilayers. Their mechanism of localization at 
the sites of infection and inflammation is by 
extravasation due to locally enhanced vascular 
permeability. Liposomes naturally target the 
mononuclear phagocytic system and radiolabeled 
liposomes are cleared rapidly from the circulation by the 
mononuclear phagocytic system. This problem can be 
avoided by coating the liposomes with hydrophilic 
polymers such as polyethylene glycol so as to avoid their 
rapid clearance from the circulation (Boerman, 
et.al.2001). 
 
Liposomes have been radiolabeled with 99mTc, either 
using hexamethyl propylene amine oxime (HMPAO) as 
an internal label or via HYNIC as an external chelator 
(Akhtar, et.al. 2012). They may be useful for the 
detection of infection and inflammation foci (Boerman, 
et.al. 2000). 
 
Technetium-99m labelled liposomes do not discriminate 
infection foci from sterile inflammation and they have 
unacceptable side effects, which limit their clinical 
application (Boerman, et.al.2001). 
 
Nanocoloids 
Nanocolloids are colloids of human serum albumin that 
measure less than 50nm in size. They have also been 
labelled with technetium-99m for the detection infection 
and inflammation foci (Flivik et.al.1993). Their 
localization at the sites of infection and inflammation is 
due to increased capillary permeability (Streule, et.al 
1988). 
Their application, however, is limited to musculoskeletal 
infections and inflammation (Das et.al 2002). 
 
MDP (methyl diphosphonate) 
99mTc-MDP is a nonspecific radiopharmaceutical that 
localizes at the site of infection and inflammation due to 
vasodilation and hyperemia. It is mainly used for 
imaging in bone infections such as osteomyelitis and 
prosthetic joint infections. Usually, it is used in 
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combination with radiolabeled WBCs to increase the 
specificity of the detection procedure. The procedure 
requires three phase bone imaging, usually taking 4 
hours post injection (Love and Palestro, 2004). 
 
The half-life of technetium-99m is sometimes not 
enough to undertake certain studies. For that reason, 
longer lived SPECT radionuclides such as I-123 may act 
as useful alternatives. 
 
Iodine-123 
Iodine is a highly volatile group seven element with an 
electronic configuration of (Kr)4d105s25p5. Its chemistry 
is dominated by both electrophilic and nucleophilic 
addition and substitution reactions (Koehler, 2010). It 
has four radionuclides that are potentially applicable for 
clinical gamma imaging applications; Iodine-120, 
Iodine-123, Iodine-124 and Iodine-131. Due to the high 
positron energy of Iodine-120 and the beta-minus 
particle emission of Iodine-131, these radioisotopes are 
not clinically applied for infection or inflammation 
imaging today. 
 
Iodine-123 decays 97% by electron capture with a half-
life of 13.2 hours to tellurium-123. In the process, 
gamma rays of 159 keV having an abundance of 83% is 
emitted (Be, 2004). The gamma energy, its abundance 
and the 13.2 hour half-life make iodine-123 well suited 
for infection and inflammation imaging, including cases 
where delayed or follow up imaging is necessary. One 
important challenge in the use of iodine-123 is its cost. 
This cost is contributed mainly because it is cyclotron 
produced. Also, the volatile nature of iodine demands 
more caution and dedicated equipment for the handling 
of radioiodine. Another challenge, like for all other 
iodine radioisotopes, is the risk of in vivo de-iodination 
and thyroid uptake of the radioiodine. 
 
Translocator protein (TSPO) 
TSPO, also called peripheral benzodiazepine receptor, is 
a mitochondrial membrane protein that is present in 
immune cells. In the CNS, it is specific for glial cells and 
astrocytes. Immune responses in the CNS are mediated 
via these cells which overexpress TSPO when they are 
activated during inflammation, (Chen, 2008). TSPO is 
therefore a useful target for the molecular imaging of 
neuroinflammation in vivo. According to Wu C. et al 
(Wu et al, 2013), radiotracers targeting this biomarker 
have been developed and clinically tested. 
 
PK11195, an isoquinoline derivative, is a high affinity 
ligand TSPO. It has been radiolabeled with iodine-123 
and clinically tested for SPECT imaging of inflammation 
in various tissues such as CNS (Versijpt, 2000) and 
myocardium (Gildersleeve, 1996) with significant 
accumulation at the inflammation sites. 
 
The challenge with this ligand is that it accumulates in 
other organs where TSPO is abundantly expressed such 
as the kidneys, myocardium and also in some cancers 
(Batarseh A., 2010). Also, it cannot differentiate sterile 
inflammation from infection. 
 
Cytokines 
Interleukin-2 - IL-2 
Interleukin-2 is a cytokine that is secreted by activated T 
cells. It has its receptors on a variety of immune cells, 
including macrophages, T cells, B cells and even NK 
cells and it is involved in both the initiation and 
termination of inflammation (Hoyer, 2008). By 
radiolabeling it with gamma emitting radioisotopes, it’s 
possible to image inflammation loci. Iodine-123 has 
already been used for that and it produced useful results 
in humans (Signore, 2000). With these findings and 
others (Annovazzi, 2003), the approach of targeting IL-2 
receptor bearing immune cells with radioisotopes for 
molecular imaging of inflammation maybe applicable for 
monitoring and individualizing therapy in patients with T 
cell and macrophage infiltrated inflammatory lesions 
such as in Crohn’s. 
 
Interleukin-1B IL-1B 
Interleukin-1B is a pro-inflammatory cytokine, produced 
majorly by activated macrophages and monocytes 
(Lopez-Castejon, 2011). It has receptors in a variety of 
immune mediating cell types, including granulocytes. 
During inflammation, these cells upregulate their 
Intrleukin 1 receptors (Fasano, 1991). Since these 
immune cells accumulate in inflammatory loci, targeting 
them for nuclear molecular imaging can be an important 
option in detecting inflammation sites and treatment 
monitoring. The radiolabeling of human recombinant 
interleukin-1 receptor antagonist (hrIL-Ira) with Iodine-
123 has already been done and it has shown preferential 
accumulation in the inflamed joints of rheumatoid 
arthritis patients with synovitis (Barrera, 2000). 
 
Similar to all other radiolabeled cytokines, it lacks ability 
to distinguish infection from sterile inflammation foci. 
 
 
PET radiopharmaceuticals for infection and 
inflammation imaging 
Since SPECT technology generally has lower resolution 
and sensitivity than PET technology. PET 
radiopharmaceuticals also given significant interest in 
the area of infection and inflammation imaging. 
 
Fluorine-18 based radiopharmaceuticals for infection 
inflammation imaging 
Fluorine is a group seventeen element in the periodic 
table with an electronic configuration of [He]2s22p5. 
Fluorine-18 is the only radioisotope of fluorine that is 
important for radiopharmaceutical application presently. 
Its radiochemistry is diverse, involving both nucleophilic 
and electrophilic reactions (Jacobson, 2010). 
 
Fluorine-18 is a positron emitting radioisotope that 
decays into Oxygen-18 with a half-life of 1.83 hours. 
97% of it decays through positron emission and the rest 
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is through electron capture. Its maximum and mean 
positron energies of 634 keV and 249 keV, respectively 
(Be et al, 2004). Its mean tissue positron range of about 
0.6 mm (Cal-Gonzalez, 2009) yields higher PET image 
resolution with fluorine-18 than with other clinically 
available positron emitting radioisotopes. The excellent 
nuclear properties and fluorine’s diverse chemistry 
(Jacobson, 2014) highlight fluorine-18’s suitability for 
infection and inflammation imaging and for most clinical 
PET applications. Indeed, fluorine-18 is currently the 
commonest positron emitting radioisotope in clinical use. 
Fluorine-18 is mainly cyclotron produced through proton 
bombardment of Oxygen-18 gas (Jacobson, 2014). 
However, fluorine-18 is still more expensive to produce 
than generator produced radioisotopes because it requires 
cyclotrons. 
 
Deoxy Glucose 
2-Deoxyglucose is a derivative of glucose on which the 
hydroxyl group at position 2 of glucose has been 
replaced with hydrogen. It has similar biochemical 
properties with glucose. Its uptake by the cells depends 
on cellular metabolic rate and abundance of the glucose 
transporter. One of the hydrogen groups can be 
substituted with radioactive fluorine-18 to make 
radiopharmaceuticals and can be used for diagnosis of 
diseases in which glucose metabolism is altered in their 
pathophysiological processes. At inflammatory sites, 
upregulation of glucose transporters and increased 
affinity to deoxy glucose by the inflammatory cells has 
been observed. These properties can be targeted for the 
imaging of infection and inflammation with 18F-
Fluorodeoxyglucose (18F-FDG) (Glaudemans et.al. 
2015). Nowadays, this agent is the most commonly used 
PET radiopharmaceutical for imaging infection and 
inflammation. 
 
18F-FDG can be used for the diagnosis of varieties of 
infectious and inflammatory disorders such as 
sarcoidosis, peripheral bone osteomyelitis, suspected 
spinal infections, FOU, metastatic infections, bacteremia 
in high-risk patients, AIDs-related FUO, vasculitis, 
abdominal infections such as inflammatory bowel 
disease, thoracic and soft-tissue infections (Jamar et.al. 
2013). 
 
The quality of the image when compare with SPECT 
imaging radiopharmaceuticals is superior. High spatial 
resolution and rapid accumulation in infectious foci are 
significant advantages 18F-FDG of over other 
radiopharmaceuticals used in conventional imaging 
techniques (Gotthardt et.al. 2010). 
 
Although 18F-FDG PET imaging is very sensitive, it does 
not discriminate infection from sterile inflammation. 
Also, it lacks ability to distinguish inflammation from 
other conditions with high glycolytic activity such as 
tumors. It has difficulty to detect infection and 
inflammation foci near to heart and brain tissues. In 
addition, the high cost and limited availability of PET 
imaging (Basu et.al 2009) restrict its wide application in 
infection and inflammation imaging. 
 
Radiolabeled WBCs have shown somewhat specificity 
towards infectious foci. Hence, an attempt to radiolabel 
WBCs with fluorine -18 has also been done. 
 
WBCs 
WBCs have been labelled with 18F-FDG to take the 
advantage of good imaging characteristics of both 18F-
FDG and WBCs for visualizing infection and 
inflammation foci. Promising results were obtained (Pio 
et.al 2003). 
 
However, the stability of 18F-FDG-WBC is weak; there 
is a rapid release of 18F-FDG from the radiolabeled 
WBCs. The half-life of fluorine -18 is too short for 
delayed imaging to be feasible, which decreases the 
specificity of the method. Furthermore, 18F-FDG-WBC 
preparation is time consuming, requires highly trained 
personnel and special equipment which make it more 
expensive than both 18F-FDG and 99mTc-HMPAO 
labeling methods (Signore et.al 2009). 
 
Apart from the tedious process of radiolabeling WBCs 
with fluorine -18, 18F-FDG-WBC still has the weakness 
of non-specificity in differentiating infection from sterile 
inflammation. 
 
Thymidine kinase substrate 
Thymidine kinase is an enzyme involved in the synthesis 
of DNA and it is found in most living cells. However, the 
isoforms present in human and bacteria are different. 
This characteristic may help to develop a substrate that is 
selectively metabolized by bacterial thymidine kinase 
and use it to formulate radiopharmaceuticals that 
selectively accumulate in infection foci. 3'-deoxy-3'-[18F] 
fluorothymidine ([18F]FLT) is a fluorine-18 labeled 
nucleoside substrate for Salmonella typhimurium 
thymidine kinase. It has shown significant accumulation 
in bacterial infection foci in mouse models (Davis et.al. 
2009 and Jang et al 2012). 
 
Other ligands for fluorine-18 for infection and 
inflammation imaging 
In addition to deoxy glucose, other ligands have been 
discovered to visualize infection and inflammation foci 
using fluorine -18 as a PET imaging radionuclide. These 
ligands target different sites and receptors involved in the 
inflammatory process. 
 
18F-choline (18FCH) targeting increased catabolism of 
phosphatidylcholine by inflammatory cells (macrophages 
and monocytes) has shown promising results in the 
detection of inflammation associated with atherosclerotic 
plaques. 18F-labeled isoquinoline carboxamide 
(PK11195), 18F-FEAC and 18F-FEDAC are radioligands 
targeting translocator protein (TSPO) that is highly 
expressed in macrophages, neutrophils, lymphocytes, 
activated microglia and astrocytes. They have shown 
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high accumulation in sites of neuroinflammation and 
other inflammatory disorders (Wu et.al 2013). 
 
Ligands that are targeting cannabinoid receptor 2 
(CB2R) have also been labeled with fluorine-18. CB2R 
is mainly over expressed on activated microlgia, the 
resident immune cells in CNS, and promising results 
have been observed for the imaging of inflammatory 
disorders in the brain tissues (Evens et.al 2011). 
 
18F-CGS27023A and other Matrix metalloprotease 
(MMP) inhibitors are ligands that inhibit matrix 
metalloproteinases (MMPs), enzymes whose activity 
increases during inflammatory conditions. They can 
possibly be the future agents for detecting inflammatory 
disorders e.g. vascular inflammation (Wu et.al 2013). 
 
Interleukin (IL)-2 is a glycoprotein synthesized and 
secreted by activated T lymphocytes. It binds to its 
specific receptor on activated lymphocytes. 
Radiolabeling this ligand with Flourine-18 (18F-FB-IL-2) 
may help to visualize activated lymphocytes in 
inflammatory disorders (Di Gialleonardo et.al 2012). 
 
RGD peptides are peptides that contain the three amino 
acid sequence Arg-Gly-Asp. They bind specifically to 
αvβ3, an integrin receptor that is expressed in activated 
inflammatory cells such as macrophages. These peptides 
have been labelled with fluorine-18 and they may be 
useful for visualizing angiogenesis in inflammation 
disorders (Wu et.al 2013). 
 
Carbon-11 based radiopharmaceuticals for infection 
and inflammation imaging 
Carbon is a group four element in the periodic table of 
elements with an electronic configuration of 1s22s22p2. It 
is a constituent of all organic molecules, hence, 
radioisotopes of carbon that have suitable nuclear 
properties are particularly useful in that they can be 
incorporated into any organic molecule and used to 
image biological processes including infections and 
inflammation. 
 
Among the carbon radioisotopes, it is carbon-11 that is 
useful for radiopharmaceuticals today. It decays with a 
half-life of 20.4 minutes to Boron-11. Over 99% of 
Carbon-11 decays by positron emission (Be, et al, 2004). 
The high yield of positrons ensures the production of 
high abundance of annihilation photons for imaging. 
Also, the average positron energy of 386 keV (Be, et al, 
2004) limits their average tissue range to about 1.0 mm 
(Cal-Gonzalez, 2009) and yield high resolution images. 
Of the currently used short-lived PET radioisotopes, 
carbon-11 is the closest to fluorine-18 in both average 
positron energy and tissue range. The major challenge 
with carbon-11 application in radiopharmaceuticals is its 
short half-life. Since it is usually produced as carbon 
dioxide gas or methane gas from the cyclotron, carbon-
11 mostly requires to be converted into chemically 
reactive species for its incorporation into 
radiopharmaceuticals (Scott, 2009). The time taken 
during such processing may significantly lead to lower 
radiolabeling yields. In addition, the short half-life 
precludes delayed imaging of the infection or 
inflammation locus. High yield production of carbon-11 
is done through proton bombardment of nitrogen-14 in a 
cyclotron (Schmor, 2011). Cyclotron production, while 
avoiding the challenges associated with reactor produced 
radioisotopes, leads to high cost of the 
radiopharmaceuticals produced. 
 
Translocator protein (TSPO) 
Translocator protein has also been targeted with its 
iodine -123 labelled high affinity ligands such as 
PK11195 for molecular SPECT imaging (refer to section 
on Iodine -123). Among the carbon-11 labeled tracers of 
this category, the commonest example is 11C-PK11195. 
In clinical trials this agent has shown preferential 
accumulation in inflammation sites (Wu C, 2013). Also, 
it may distinguish inflammation from some tumors. 
 
Cannabinoid receptor 2 
The main cannabinoid receptor that is associated with 
anti-inflammatory properties in the brain is CB2R 
(Miller, 2008). It is constitutively expressed in low 
amounts but its expression is upregulated in activated 
microglial cells, perivascular macrophages and other 
immune cells during inflammation (Benito, 2005). 
Imaging CB2R can be an important tool for diagnosing 
and monitoring neuroinflammation. Tracers such as 11C-
A-836339, 11C-Sch 225336, [C11]NE40 and 11C-
GW405833 have been developed, but mainly in the pre-
clinical stages (Wu, C. 2013). 
 
Fluorine-18 and carbon-11 are produced from cyclotron, 
making them expensive. Gallium- 68 is produced from 
generators and it can serve as a cheaper alternative for 
PET. 
 
Galium-68 
Gallium-68 decays 89% by positron emission and 11% 
by electron capture, with a half-life of 1.13 hours to zinc-
68. 88% of the times, it emits positrons having mean 
energy of 844 keV (Delacroix, 2002) and a simulated 
mean tissue range of 2.21mm (Cal-Gonzalez 2009). It is 
available for clinical application mainly through the 
germanium-68/gallium-68 generator (Velikyan, 2015). 
 
Its commercial availability from the inexpensive 
germanium-68/gallium-68 generator makes the 
radioisotope less costly than cyclotron produced 
radioisotopes. Also, its high positron yield means that it 
achieves high abundance of its 511 keV annihilation 
gamma rays. The 270-day half-life of the parent 
(germanium-68) allows for a very long working life of 
the generator (one year). Some of its limitations are that 
its positrons have a higher mean energy and a longer 
tissue range, hence poorer image resolution than seen 
with other positron emitting radioisotopes such as 
carbon-11, fluorine-18 and copper-64 (Cal-Gonzalez 
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2009). Its half-life of 68 minutes is also unsuitable for 
labeling slow plasma clearing molecules. 
 
Successful usage of gallium-67 citrate with SPECT lead 
to the application of positron emitting gallium-68 for 
infection and inflammation imaging. 68Ga-Citrate and 
68Ga-transferrin have been used as PET alternatives to 
gallium-67 citrate imaging. They have been used for the 
detection of bone infections such as osteomyelitis 
(Kumar and Boddeti, 2013). However, the short half-life 
of 68Ga is a challenge since these agents require delayed 
imaging, just as with 67Ga-citrate. 
 
Small peptides have fast kinetics and they are rapidly 
cleared from plasma and other non-target tissues, making 
them interesting ligands for the short half-life positron 
emitting gallium-68. Peptide-based radiopharmaceuticals 
that are radiolabeled with gallium-68 have been 
developed to detect infection and inflammation foci. A 
pre-clinical study on the antimicrobial peptide TBIA101 
labeled with gallium-68 (68Ga-DOTA-TBIA101) 
targeting bacterial lipopolysaccharides has shown 
localization in E. coli infected tissues (Mokaleng et al, 
2010). 
 
Recently, it has been shown that a peptide the Siglec-9 
targets vascular adhesion protein 1 (VAP-1). VAP-1 is a 
human endothelial protein whose cell surface expression 
is induced under inflammatory conditions. It controls the 
extravasation of leukocytes. 68Ga-DOTA-Siglec-9 was 
developed and tested in clinical studies where it has 
demonstrated significant accumulation in S. epidermidis 
or S. aureus infected rat tissues (Ahtinen, H et.al 2014). 
The hemoglobin scavenger receptor CD163 is 
overexpressed in a large range of inflammatory diseases. 
68Ga labeled anti-CD163-antibody for arthritis imaging 
in rodent PET showed promising results (Christensen 
et.al 2015). 
 
Over-expression of somastatin receptors (SSTR) on 
activated lymphocytes and macrophages has been 
observed. Peptide ligands such as TATE (Tyr octreotate) 
and TOC (Tyr octreotide) octreotide analogue that binds 
to somastatin receptor 2(SSTR2) have been labeled with 
68Ga through DOTA-derived bifunctional chelators. They 
have been used to visualize inflammation foci in 
atherosclerosis, pulmonary fibrosis as well other 
conditions. These radiopharmaceuticals are especially 
important in imaging of coronary artery plaques since 
there have low uptake in the myocardium (Pettinato et.al 
2008 & Banerjee and Pomper, 2013). 
 
Long lived PET radionuclide. 
Since the above PET radionuclides have a short half-
lives, longer lived PET radionuclides would offer the 
advantage of studying the uptake of the tracers for longer 
periods of time. 
 
 
 
I-124 
Targeting enzymes 
Enzymes that are specific for, or more abundant in, 
inflammatory cells or pathogens are potential targets for 
molecular imaging of inflammation and infection using 
radiolabeled enzyme substrates. The important factor 
about this approach is that the enzyme must be substrate-
specific and its products must be selectively retained 
within the target cells or tissues so as to minimize the 
background uptake of the radiotracer. Enzymes that have 
already been targeted include Matrix Metalloproteinases 
(MMP), Caspases and Thymidine kinase. 
 
Matrix metalloproteinases - MMP 
Matrix metalloproteinases are a class of proteolytic 
enzymes that are produced constitutively in 
physiological amounts in almost all tissues, where they 
have multiple physiological roles (Loffeck, 2011). Also, 
they have been implicated in pathologies such as 
inflammatory diseases, etc. where they are significantly 
overexpressed in the affected loci (Muller-Quernheim, 
2011). By radiolabeling specific inhibitors of these 
enzymes, in vivo imaging of inflammation loci has been 
successful in animal models. For instance, Hartung et al. 
showed that 124I-HO-MIP (CGS 27023A) preferentially 
accumulated in loci of carotid inflammation in mice 
(Hartung et al, 2007). 
 
Thymidine Kinase 
Thymidine kinase is a phosphotransferase that catalyzes 
the conversion of thymidine to thymidine 
monophosphate, an important process in nucleic acid 
synthesis. Even though the enzyme is ubiquitously 
expressed in both prokaryotes and eukaryotes, there are 
significant differences in the isoforms and also substrate 
specificity (Wellin, 2004). This difference has been 
exploited using 124I-FIAU for the molecular imaging of 
bacterial infections. 124I-FIAU is a specific substrate of 
the bacterial isoforms of the enzyme (Diaz, 2007). One 
advantage of this approach is the possibility of 
differentiating infection from sterile inflammation. 
However, some clinical studies have posted poor 
outcomes. (Zhang et.al. 2016). 
 
Monoclonal antibodies 
Targeting CD20 
CD20 is a B-cell specific surface antigen that is 
important for B cell activation and function (Kuijpers, 
2010). In some inflammatory conditions such as 
rheumatoid arthritis, B cell infiltration and accumulation 
into inflamed joints occurs in some patients (Bugatti, 
2014). In such patients, rituximab, an anti-CD20 
monoclonal antibody, is still applied for their therapy. 
Therefore, molecular imaging to determine B cell 
infiltration in rheumatoid arthritis patients can be very 
valuable for patient classification, individualizing 
therapy and patient monitoring. For PET imaging of B 
cell infiltration of inflamed joints, 124I-rituximab 
demonstrated clinical usefulness in clinical studies (Tran, 
2011). 
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Copper-64 based radiopharmaceuticals for infection 
and inflammation imaging 
Copper is a transition metal with an electronic 
configuration of [Ar]3d104s1. Its radiopharmaceutical 
chemistry is dominated by its +2 oxidation state (Cai, 
2014). In this state, copper is able to form stable 
complexes with nitrogen-containing bifunctional 
chelating agents that can subsequently be chemically 
attached to bioactive molecules for imaging biological 
processes. Radioisotopes of copper that have potential 
usefulness in imaging include copper-60, copper-61, 
copper-62 and copper-64. However, copper-64 is the 
commonest applied for clinical positron emission 
tomography because of its appealing nuclear properties. 
Copper-64 decays with a half-life of 12.7 hours by beta-
minus emission to zinc-64 (39%), positron emission 
(18%) and electron capture to Nickel-64 (Be, 2004). Its 
maximum positron energy of 653 keV (Be, 2004) and 
mean positron range are similar to those of fluorine-18 
(Belov, 2011). Hence, the image resolution is expected to 
be similar to that obtained from fluorine-18 scans. Its 
half-life is also long enough for the performance of 
delayed and longitudinal imaging. 
 
Some challenges with copper chemistry include the low 
in vivo stability of many of its complexes (Zhengxin, 
2014), causing high radiocopper uptake by non-target 
tissues. Its high abundance beta-minus emission is 
another challenge because it may contribute to high 
unwanted radiation dose to the patient. Also, the cost of 
copper-64 is high since it’s produced through the 
cyclotron. 
 
Currently, there are a few ligands that have been labelled 
with copper-64 for the detection of infection and 
inflammation foci. 
 
WBCs 
WBCs have also been labeled with copper-64 for 
infection and inflammation imaging. 64Cu-WBCs 
labeling efficiency and viability were comparable or 
superior to 111In-WBCs, and significantly higher than 
18F-FDG-WBCs in human volunteers (Bhargava et.al. 
2009). 
 
Formyl peptide receptor (FPR) ligands 
FPR is a type of G-protein coupled receptor expressed on 
neutrophils. It is involved in chemotaxis (Le et.al. 2001). 
The peptide cinnamoyl-F-(D)L-F-(D)L-F (cFLFLF) is an 
antagonist to the FPR. It has been labelled with Cu-
64(cFLFLFK-PEG-(64) Cu) and showed significant 
accumulation in lungs of a Klebsiella infected mouse 
model (Locke et.al. 2009). 
 
RGD peptides 
RGD peptides are ligands that bind to Integrin αvβ3, a 
cell adhesion molecule. αvβ3 is overexpressed in some 
inflammatory cells, such as macrophages. The 
radioligand 64Cu-DOTA-E[c (RGDyK)] 2}2 that binds to 
integrin αvβ3 has shown promising results in imaging the 
chronic inflammation process (Cao et.al. 2007). 
 
Natriuretic peptide 
64Cu-labeled atrial natriuretic peptide (64Cu-DOTA-C-
ANF) has been applied for the detection of 
atherosclerotic plaques on rabbit (Liu et.al 2010) 
 
Anti-b7 integrin antibody 
Integrins are cell surface glycoprotein receptors that are 
involved in leucocyte adhesion, signaling, proliferation 
and migration by binding as heterodimers to specific 
ligands. The β7 integrin forms heterodimers with ligands 
expressed on lymphocytes, and other cells to mediate 
leucocyte infiltration into the gastrointestinal tract 
(Stefanich et.al. 2011). 64Cu-labeled anti-b7 integrin 
antibody has shown significant uptake in dextran sulfate 
sodium (DSS) induced colitis in mice (Dearling and 
Packard, 2012) 
 
Nanoparticle 
64Cu-labelled chitosan-coated magnetic nanoparticles are 
taken up by granulocytes through phagocytosis. They 
have shown suitability for use as infection and 
inflammation radiopharmaceuticals. (Pala et.al. 2012) 
 
Zirconium-89 based radiopharmaceuticals 
Zirconium is a group four transition metal with an 
electronic configuration of [Kr]4d25s2. Zirconium, in its 
+4 oxidation state, forms stable complexes with nitrogen 
and oxygen containing electron donor ligands. The 
commonest ligands studied are bifunctional chelators 
based on desferrioxamine for radiolabeling of 
biomolecules (W Severin, 2011). Ziconium-89 is the 
commonest studied zirconium isotope for 
radiopharmaceutical application. It decays by positron 
emission (23%) and electron capture with a half-life of 
78.43 hours (3.27 days) to Yttrium-89 (Kocher, 1981). 
Apart from the advantages of its long half-life, its 
average positron energy of 397 keV (Kocher, 1981) may 
achieve an image resolution similar to that of carbon-11 
imaging since it has similar mean positron energy. 
However, its emission of high abundance (99%) high 
energy photons (909 keV) (Kocher, 1981) and its high 
cost of production from cyclotron constitute some of its 
important limitations. 
 
Currently, there are a few ligands that have been labelled 
with zirconium-89 and used for the detection of infection 
and inflammation foci. WBCs were labelled with 
zirconium-89-loaded chitosan nanoparticles (CN) and 
copper-64-loaded CN. 89Zr-loaded-CN showed fast 
kinetics of leukocyte association, high labelling 
efficiency and a relatively good intracellular retention of 
the radioactivity than copper-64-loaded CN (Fairclough 
et.al. 2016). 
 
In another study 89Zr-oxalate was compared with [18F] 
FDG and sodium [18F] fluoride. 89Zr-oxalate showed 
higher selectivity index to inflammation at a delayed 
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time point after injection (24 h) than [18F]FDG and 
sodium [18F]fluoride. Significant uptake in inflammatory 
lesions of a mouse model of rheumatoid arthritis (RA) 
was also revealed (park et.al. 2016). 
 
Other promising radionuclides 
Manganese radioisotopes 
Manganese is a group seven transition metal. A number 
of radioisotopes of manganese are potentially useful for 
radioimaging of biological processes such as infection 
and inflammation. They include Manganese-52 and 
Manganese-52m. Manganese-52 decays by positron 
emission (29%) and electron capture to Chromium-52 in 
a half-life of 5.6 days while Manganese-52m decays to 
Manganese-52 (96%) in a half-life of 21.2 minutes 
(Delacroix, 2002). Manganese-52, because of its long 
half-life of 5.6 days is more useful for imaging slow 
biological processes and radiolabeling large 
biomolecules of slower in vivo kinetics than Manganese-
52m. With maximum and average positron energies of 
575 keV and 241 keV respectively, Manganese-52 may 
yield images of better resolution than Manganese-52m 
which emits high abundance (96.6%) positrons with an 
average energy of 1172 keV (Kocher, 1981). 
 
Terbium radioisotopes 
Terbium is a lanthanide of atomic number 65 and an 
electronic configuration of [Xe]4f96s2. It has two 
radioisotopes that are potentially useful for clinical 
imaging applications; Tb-152 for PET and Terbium-155 
for SPECT. Terbium-152 decays by positron emission 
(17%) and electron capture to gadolinium-152 in a half-
life of 17.5 hours (Muller, 2012). It’s one main weakness 
is its high average positron energy of 1080 keV. 
Terbium-155, on the other hand, decays 100% by 
electron capture in a half-life of 5.32 days to gadolinium-
155 with the emission of a spectrum of gamma rays. The 
high abundance gamma rays of 86.6 keV (32%) and 
105.3 keV (25%) are useful for clinical imaging (Muller, 
2012). Its half-life is also long enough for imaging of 
radiopharmaceuticals that possess slow in vivo kinetics. 
 
CONCLUSION 
Radiopharmaceutical are providing very important 
advantages over other diagnostic modalities for the 
diagnosis and monitoring of infectious and inflammatory 
disorders. Hence, interest in this area has increased in the 
last decade. However, the currently used 
radiopharmaceuticals are still far from ideal; for instance, 
they lack capability to differentiate infections from 
sterile inflammation. Many radiopharmaceuticals have 
been studied, so far, but still only few of them are in 
practice today. Therefore, it is important to accelerate the 
development of clinically viable radiopharmaceuticals 
for this area. 
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